Stowers Institute for Medical Research, 1000 East 50th Street, Kansas City, Missouri 64110, USA.
Nat Rev Cancer. 2010 Oct;10(10):721-8. doi: 10.1038/nrc2915. Epub 2010 Sep 16.
The RNA polymerase II (Pol II) elongation factor (ELL) was the first translocation partner of mixed lineage leukaemia (MLL) for which a biochemical function was determined. It was therefore proposed that the regulation of the elongation stage of transcription could be fundamental to MLL-based leukaemogenesis. Recent studies have identified ELL complexed with several of the translocation partners of MLL in a transcriptional super elongation complex (SEC). These studies provide evidence for the importance of the regulation of Pol II elongation in disease pathogenesis and suggest that MLL chimaeras function by licensing Pol II transcription elongation without the appropriate checkpoints.
RNA 聚合酶 II（Pol II）延伸因子（ELL）是第一个被确定具有生化功能的混合谱系白血病（MLL）易位伙伴。因此，有人提出，转录延伸阶段的调控可能是 MLL 白血病发生的基础。最近的研究已经鉴定出 ELL 与 MLL 的几个易位伙伴在转录超延伸复合物（SEC）中形成复合物。这些研究为 Pol II 延伸调控在疾病发病机制中的重要性提供了证据，并表明 MLL 嵌合体通过许可 Pol II 转录延伸而不经过适当的检查点来发挥作用。
